Author(s): Martins, Ivone M. ; Silva, Ana Isabel M. ; Azeredo, Joana ; Kessels, Helmut
Date: 2018
Persistent ID: https://hdl.handle.net/1822/55413
Origin: RepositóriUM - Universidade do Minho
Author(s): Martins, Ivone M. ; Silva, Ana Isabel M. ; Azeredo, Joana ; Kessels, Helmut
Date: 2018
Persistent ID: https://hdl.handle.net/1822/55413
Origin: RepositóriUM - Universidade do Minho
[Excerpt] Alzheimer´s Disease (AD) is an age-dependent neurodegenerative disease with very high incidence worldwide and detrimental consequences. Manifests as a decline in cognitive functions and memory loss, characterized at molecular level by an increased deposition of amyloid-beta (AB) plaques. Nevertheless, it is AB in the still-soluble oligomeric/fibrillar form that impairs synaptic function and memory encoding [1]. Therefore, new tools that selectively target AB oligomers/fibrils in the brain hold great potential to halt AD at an early stage. Specific amyloidogenic peptide motifs grafted into an antibody, were described to react with AB fibrils: AB30-39, and with fibrils and oligomers: AB33-42 [2]. However, the blood-brain-barrier, by sheltering the central nervous system from the systemic circulation, is a major bottleneck for peptide- and antibody-based applications. To overcome this limitation, bacteriophages and phage display can be applied [3,4]. [...]